Gynecological cancer: First-line bevacizumab for ovarian cancer - New standard of care?

Abstract

Demonstration of the clinically significant activity of bevacizumab in advanced-stage ovarian cancer has attracted a great deal of interest. Here, we summarize the two positive phase III trials that led to EMA approval of bevacizumab as first-line therapy and discuss the optimum use of the drug in this disease. © 2012 Macmillan Publishers Limited. All rights reserved.